Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $226.62 and last traded at $208.28, with a volume of 269293 shares traded. The stock had previously closed at $141.97.
Analysts Set New Price Targets
A number of brokerages recently issued reports on ALNY. Guggenheim lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 27th. HC Wainwright boosted their target price on shares of Alnylam Pharmaceuticals from $400.00 to $430.00 in a research note on Monday, May 2nd. BMO Capital Markets boosted their target price on shares of Alnylam Pharmaceuticals from $166.00 to $192.00 and gave the company a “market perform” rating in a research note on Thursday. Chardan Capital boosted their target price on shares of Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Cantor Fitzgerald started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 12th. They set a “neutral” rating and a $175.00 target price for the company. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $225.75.
Alnylam Pharmaceuticals Stock Up 5.7 %
The firm has a market cap of $26.89 billion, a price-to-earnings ratio of -27.42 and a beta of 0.74. The firm’s fifty day moving average is $143.40 and its two-hundred day moving average is $147.42. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.76 and a quick ratio of 3.62.
Insider Buying and Selling
In related news, EVP Tolga Tanguler sold 1,754 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $150.00, for a total value of $263,100.00. Following the completion of the sale, the executive vice president now owns 1,754 shares of the company’s stock, valued at $263,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.40% of the company’s stock.
Institutional Investors Weigh In On Alnylam Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. UMB Bank N A MO acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at about $28,000. FSB Premier Wealth Management Inc. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $30,000. KRS Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $37,000. Finally, CKW Financial Group lifted its holdings in Alnylam Pharmaceuticals by 50.0% in the 1st quarter. CKW Financial Group now owns 300 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 100 shares during the last quarter. 92.39% of the stock is owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- 3 Hotel Stocks to Consider Checking into After Earnings
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- These Are The Top Insider Buying Stocks For July
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.